Jiangsu Aidea Pharmaceutical Co.Ltd(688488) announcements, the company and its subsidiary, awesome, signed a technology transfer contract with Lixin bio on the ACC006 project of the company’s anti-tumor drug research and development company. The company transferred all the rights related to the technical secrets and patents of the company’s projects with the company’s resources to Li Xin biological, Lixin biological transferee project and paid the technology transfer fee of 100 million yuan (including tax). The subject project has completed preclinical research and phase I and phase IB clinical research. At present, a multicenter, randomized, double-blind, parallel controlled phase II clinical trial of albumin bound paclitaxel and carboplatin (NAB PC) in the treatment of advanced squamous non-small cell lung cancer is being carried out.
(Shanghai Securities News · China Securities Network)
